Rgenta Therapeutics

About

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Cambridge,Massachusetts,United States
1 - 10
https://www.rgentatx.com/

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $52M
Industries: Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2018
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Rgenta Therapeutics Inc.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.

It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$108.94M

Rgenta Therapeutics has raised a total of $108.94M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2022 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 29, 2022	Series A	$52M	10	AstraZeneca CICC	—	Detail
Feb 7, 2022	Series Unknown	$8.91M	—	—	—	Detail
May 25, 2021	Seed	$18M	3	—	—	Detail
Apr 2, 2020	Seed	$20M	4	Boehringer Ingelheim Venture Fund Matrix Partners China	—	Detail
Jan 21, 2020	Series Unknown	$10.03M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

10

Rgenta Therapeutics is funded by 10 investors. AstraZeneca and CICC are the most recent investors.

Investor Name	Lead Investor	Funding Round
AstraZeneca	Yes	Series A
CICC	Yes	Series A
Boehringer Ingelheim Venture Fund	—	Series A
Delos Capital	—	Series A
Kaitai Capital	—	Series A
Korean Investment Partners	—	Series A
Legend Star	—	Series A
Lilly Asia Ventures	—	Series A
Matrix Partners China	—	Series A
Vivo Capital	—	Series A